Skip to Content


Active Substance: gadoversetamide
Common Name: gadoversetamide
ATC Code: V08CA06
Marketing Authorisation Holder: Mallinckrodt Deutschland GmbH
Active Substance: gadoversetamide
Status: Withdrawn
Authorisation Date: 2007-07-23
Therapeutic Area: Magnetic Resonance Imaging
Pharmacotherapeutic Group: Contrast media

Therapeutic Indication

This medicinal product is for diagnostic use only.

Optimark is indicated for use with magnetic resonance imaging (MRI) of the central nervous system (CNS) and liver. It provides contrast enhancement and facilitates visualisation and helps with the characterisation of focal lesions and abnormal structures in the CNS and liver in patients with known or highly suspected pathology.

The marketing authorisation for Optimark has been withdrawn at the request of the marketing authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.